ACOTEC-B

Acotec Scientific plunged today, closing at HKD 6.295, down 5.3% from the previous close of HKD 6.645, hitting an intraday low of HKD 6.295 in the afternoon session. The sharp decline was driven by its H1 2026 earnings swing to a net loss of RMB 80.83 million, with revenue falling 5.6% to RMB 331.58 million, missing consensus; Q2 net loss stood at HKD 46.65 million, a 196% YoY deterioration, and EPS was -HKD 0.1558. Despite recent regulatory approvals for AcoArt Canna® balloon, micro-guidewire, and a radiofrequency ablation system in China and the US, the fundamental deterioration weighed heavily. The stock is now 59.3% below its 52-week high of HKD 15.47, merely 5.1% above the 52-week low of HKD 5.99, and trades below both the MA20 (HKD 6.864) and MA60 (HKD 7.684), with a YTD decline of 54.2%. However, SDIC Securities maintained a Buy rating, and the pipeline of new product approvals may offer some support.

Acotec Scientific staged a morning session reversal, closing at 11:28 BJ at HKD 6.795, up 5.51% from its previous close of HKD 6.44, shrugging off the H1 loss warning from terminating a US clinical project. The stock traced a bottom-fishing pattern, rising from an intraday low of HKD 6.39 to the session high of HKD 6.795. Despite projecting a H1 net loss of up to RMB 80.9 million, Q4 2025 results showed revenue grew 27% YoY to HKD 163 million and net profit surged 160% YoY to HKD 17 million, underscoring the underlying earnings recovery. However, at HKD 6.795, the stock remains below its 20-day MA (HKD 7.179) and 60-day MA (HKD 7.87), with a YTD decline of 50.51% and a 56% discount to its 52-week high of HKD 15.47, suggesting the valuation repair is still in its early stages.

Acotec Scientific-B surged 5.14% in the morning session to close at HKD 6.44, driven by a deep strategic partnership with Boston Scientific and a series of product registration approvals including guidewires and coronary balloon catheters, which offset the negative impact of a halted US clinical trial that led to an H1 net loss. Despite strong Q4 2025 revenue growth of 26.93% YoY and net profit growth of 159.62% YoY, the stock is down 53.1% YTD and 58.37% from its 52-week high of HKD 15.47, trading below both the 20-day MA of HKD 7.395 and 60-day MA of HKD 7.993, with a PE of 15.28x and PB of 1.23x.

Acotec Scientific opened lower and extended losses by 9:39 AM BJ, falling 5.5% as the market digested its H1 2026 net loss warning, which could be up to RMB 80.9 million, and the uncertainty around its AI strategic shift. This contrasts with the full-year 2025 net profit growth of 128% to RMB 119 million. The stock traded at HKD 6.16, hitting its 52-week low, well below the 20-day moving average of HKD 7.716 and 60-day MA of HKD 8.183, with a YTD decline of 55.13%. Though recent FDA 510(k) clearance for its radiofrequency ablation system and domestic product approvals provide underlying support.

Acotec Scientific tumbled 6.1% in the morning session, hitting a new 52-week low of HKD 7.225 by 09:31 BJ on thin volume of 28,000 shares. The sharp decline follows the company's H1 2026 net loss warning of up to RMB 80.9 million, reversing from a profit position. Despite strong FY2025 results with net profit up 128% to RMB 119 million and Q4 revenue growth of 26.9% YoY, the sudden mid-term swing to loss caught the market off guard. The stock now trades 53.3% below its 52-week high of HKD 15.47 and is down 47.4% YTD, with current price well below both the MA20 (7.826) and MA60 (8.236). While the near-term outlook appears challenged, recent product approvals including the FDA 510(k) clearance for its radiofrequency ablation system and new catheter registrations may provide a catalyst for recovery.